

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

---

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March 2018

Commission File Number: 001-34541

**CHINA CORD BLOOD CORPORATION**

(Translation of registrant's name into English)

**48<sup>th</sup> Floor, Bank of China Tower  
1 Garden Road  
Central  
Hong Kong S.A.R.**  
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- \_\_\_\_\_

---

---

**This report and each of the exhibits to this report are hereby incorporated by reference into the registration statements on Form F-3 (No. 333-183143 and No. 333-213730) of the Company.**

**Other Events**

On March 16, 2018, China Cord Blood Corporation (the “Company”) issued a press release announcing the results of its extraordinary general meeting of shareholders, which was held on March 16, 2018, in Hong Kong (the “Extraordinary General Meeting”). At the Extraordinary General Meeting, shareholders approved the change of the name of the Company from “China Cord Blood Corporation” to “Global Cord Blood Corporation”. The Company expects to receive approval from the Registrar of Companies in the Cayman Islands for the name change in the next several days and that it will begin trading under the new name “Global Cord Blood Corporation” on the New York Stock Exchange with effect from March 22, 2018 under a new CUSIP of G39342 103 and ISIN of KYG393421030 but still with ticker symbol “CO”.

A copy of the press release is attached hereto as exhibit 99.1.

**Exhibits**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release, dated March 16, 2018, regarding results of Extraordinary General Meeting

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CHINA CORD BLOOD CORPORATION**

By: /s/ Albert Chen  
Name: Albert Chen  
Title: Chief Financial Officer

Dated: March 16, 2018



**China Cord Blood Corporation Announces Results of  
Extraordinary General Meeting of Shareholders to  
Change Company Name to “Global Cord Blood Corporation”**

**HONG KONG, China, March 16, 2018 - China Cord Blood Corporation** (NYSE: CO) (“CCBC” or the “Company”), a leading cord blood banking operator in China, today announced the results of its extraordinary general meeting of shareholders, which was held on March 16, 2018, in Hong Kong S.A.R., China (the “Extraordinary General Meeting”).

At the Extraordinary General Meeting, shareholders approved the Company’s name to change from “China Cord Blood Corporation” to “Global Cord Blood Corporation” (“GCBC” or the “New Name”). The Company expects to receive approval from the Registrar of Companies in the Cayman Islands for the name change in the next several days and that GCBC’s ordinary shares will commence trading under the New Name on the New York Stock Exchange with effect from March 22, 2018 under a new CUSIP of G39342 103 and ISIN of KYG393421030 but still with ticker symbol “CO”. The website address of the Company will be changed to <http://www.globalcordbloodcorp.com>.

The change of Company name will not affect any of the rights of the existing shareholders of the Company. All share certificates of the Company in issue bearing the former name of the Company continue to be evidence of title and valid for all purposes (including for the purposes of trading, settlement, registration and delivery). New share certificates of the Company which are issued on or after March 22, 2018 will be issued under the New Name of the Company.

**About China Cord Blood Corporation**

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and no new licenses will be granted before 2020 in addition to the seven licenses authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company’s website at <http://www.chinacordbloodcorp.com>.

**Safe Harbor Statement**

*This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the U.S. Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.*

**For more information, please contact:**

China Cord Blood Corporation  
Investor Relations Department  
Tel: (+852) 3605-8180  
Email: [ir@chinacordbloodcorp.com](mailto:ir@chinacordbloodcorp.com)

ICR, Inc.  
Mr. William Zima  
Tel: (+86) 10-6583-7511 (China) or (+1) 646-405-5185 (U.S.)  
Email: [william.zima@icrinc.com](mailto:william.zima@icrinc.com)

---